title: BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.
authors.forename: N C P
authors.initials: NC
authors.lastname: Cross
authors.forename: G Q
authors.initials: GQ
authors.lastname: Daley
authors.forename: A R
authors.initials: AR
authors.lastname: Green
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
authors.forename: C
authors.initials: C
authors.lastname: Jamieson
authors.forename: P
authors.initials: P
authors.lastname: Manley
authors.forename: T
authors.initials: T
authors.lastname: Mughal
authors.forename: D
authors.initials: D
authors.lastname: Perrotti
authors.forename: J
authors.initials: J
authors.lastname: Radich
authors.forename: R
authors.initials: R
authors.lastname: Skoda
authors.forename: S
authors.initials: S
authors.lastname: Soverini
authors.forename: W
authors.initials: W
authors.lastname: Vainchenker
authors.forename: S
authors.initials: S
authors.lastname: Verstovsek
authors.forename: J-L
authors.initials: JL
authors.lastname: Villeval
authors.forename: J M
authors.initials: JM
authors.lastname: Goldman
mesh_terms: D002908:Chronic Disease; D002986:Clinical Trials as Topic; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D042822:Genomic Instability; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000473:pathology / Q000628:therapy
chemical_list: D016044:Fusion Proteins, bcr-abl; C507924:JAK2 protein, human; D053614:Janus Kinase 2